COMMUNIQUÉS West-GlobeNewswire

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

25/09/2024 - 22:00

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses [...]

Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024

25/09/2024 - 22:00

Le recrutement dans l'étude clinique NATiV3 progresse, avec plus de 85 % du nombre cible de patients randomisés dans la cohorte principale et d'une puissance statistique de l'étude qui devrait être supérieure à 95 % [...]

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

25/09/2024 - 22:00

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic [...]

HOOPP President & CEO Jeff Wendling announces retirement

25/09/2024 - 21:00

TORONTO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Jeff Wendling, President & CEO of the Healthcare of Ontario Pension Plan (HOOPP), announced today that he will be retiring in 2025 after more than a quarter of a century [...]

Nextech Launches Expanded Payments Functionality

25/09/2024 - 20:30

New Features to Enhance Patient Experience and Increase Speed to Revenue TAMPA, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices, [...]

Multiple Myeloma Research Foundation (MMRF) Presents New Data from Multiple Myeloma Research Programs at the 21st International Myeloma Society Annual Meeting

25/09/2024 - 18:00

Findings reinforce the value of the MMRF’s integrated clinical and translational research expertise to provide a deeper understanding of multiple myeloma and improve how the disease is treated The MMRF CoMMpass SM Study [...]

SLEEVER® and CARBIOS globally launch world’s first Home Compost biodegradable tamper evident seal: SEELCAP® ONEGO

25/09/2024 - 18:00

The SEELCAP® ONEGO innovation is the fruit of a long-term partnership between SLEEVER® and CARBIOS that combines their expertise to produce more environmentally friendly packaging security SEELCAP® ONEGO will be [...]

SLEEVER® et CARBIOS lancent le premier concept de témoin d’effraction Home Compost biodégradable sur le marché mondial : SEELCAP® ONEGO

25/09/2024 - 18:00

L’innovation SEELCAP® ONEGO est le fruit du partenariat long terme entre SLEEVER® et CARBIOS qui conjuguent leurs expertises pour la sécurisation d’emballages plus respectueux de l’environnement SEELCAP® ONEGO sera [...]

GUERBET : Résultats semestriels 2024.

25/09/2024 - 17:45

Résultats semestriels 2024 Activité très dynamique Chiffre d’affaires du 1 er semestre : 419,2 M€, en hausse de 11,8% à TCC 1 Une trajectoire portée par l’ensemble des activités et des zones géographiques Solide [...]

GUERBET : H1 2024 results.

25/09/2024 - 17:45

H1 2024 results Very dynamic business activity H1 revenue: €419.2m, up 11.8% at CER 1 A trajectory driven by all activities and geographical areas Solid increase in profitability The restated EBITDA margin 2 was 15.4%, [...]

PHAXIAM : RAPPORT FINANCIER SEMESTRIEL

25/09/2024 - 17:45

Rapport Financier Semestriel 30 Juin 2024 PHAXIAM Pièce jointe PHXM_RFS_2024

PHAXIAM Provides Business and Financial Update For the First Half of 2024

25/09/2024 - 17:45

Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections [...]

PHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024

25/09/2024 - 17:45

Engagement continu pour créer un leader mondial de la phagothérapie pour traiter des infections bactériennes sévères et résistantes Une stratégie de développement ambitieuse en ligne avec les objectifs fixés pour le [...]

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

25/09/2024 - 17:31

KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. ("Protech"), a leading [...]

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

25/09/2024 - 16:45

- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across [...]

Boehringer Ingelheim expands cancer research at its Vienna site

25/09/2024 - 16:45

Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space Over the past five years, Boehringer’s capital investments [...]

LifeLabs to Honour National Day for Truth and Reconciliation with Educational Initiatives and Community Support

25/09/2024 - 16:19

Vancouver, B.C., Toronto, ON, Sept. 25, 2024 (GLOBE NEWSWIRE) -- On September 30, LifeLabs will pause operations to recognize National Day for Truth and Reconciliation and Orange Shirt Day. This day honours the lost [...]

Capsa Healthcare Unveils the New Tryten P-Series: Engineering a Path to Better Care

25/09/2024 - 16:12

COLUMBUS, Ohio, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare, a leader in purposefully designed integrated solutions, proudly announces the launch of the new Tryten P-Series tablet and monitor carts that are [...]

Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia

25/09/2024 - 16:00

Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia LOS ANGELES, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Spinogenix, [...]